Get the Stockscreener App
21.10
0.24%
0.05
After Hours:
21.10
Newamsterdam Pharma Company Nv stock is traded at $21.10, with a volume of 756.32K.
It is up +0.24% in the last 24 hours and down -18.38% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
See More
Previous Close:
$21.05
Open:
$21.05
24h Volume:
756.32K
Relative Volume:
0.86
Market Cap:
$2.26B
Revenue:
$14.09M
Net Income/Loss:
$-176.94M
P/E Ratio:
-9.814
EPS:
-2.15
Net Cash Flow:
$-141.24M
1W Performance:
-3.08%
1M Performance:
-18.38%
6M Performance:
+30.01%
1Y Performance:
+5.50%
1-Day Range:
$19.60
$22.00
1-Week Range:
$19.60
$23.24
52-Week Range:
$15.19
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
21.10 | 2.26B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News
H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Still a Buy? - MarketBeat
China Universal Asset Management Co. Ltd. Purchases Shares of 19,589 NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
How To Trade (NAMSW) - Stock Traders Daily
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownTime to Sell? - MarketBeat
Newamsterdam pharma's COO sells $3.1 million in stock - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World
Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com UK
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire
Cardiovascular Drug Developer NewAmsterdam Pharma Takes Center Stage at Elite Biotech Conference - StockTitan
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN
Trend Tracker for (NAMS) - Stock Traders Daily
Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times
NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan
Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat
State Street Corp Purchases 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
State Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Brokers Offer Predictions for NAMS FY2024 Earnings - Defense World
FY2024 Earnings Estimate for NAMS Issued By HC Wainwright - MarketBeat
(NAMSW) On The My Stocks Page - Stock Traders Daily
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):